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SUMMARY 
 
Consensus has yet to emerge regarding the optimal choice of therapy in the management of malignant 
pericardial effusion.  We review the literature to evaluate the existing evidence on the clinical 
effectiveness of surgical and interventional cardiological approaches.  
A formal literature search for all studies addressing the treatment of pericardial effusion in cancer 
patients was undertaken using pre-defined keywords.  Abstracts were screened, reviewed and data 
extracted.  Data on intervention type, number of patients treated, number of patients surviving the 
procedure, effusion recurrences, need for further interventions, and procedure-related complications 
were obtained from each study and collated in a quantitative synthesis.  
Of 1181 articles identified, 59 contained sufficient quantitative information to be included in the 
synthesis.  A total of 2322 patients with symptomatic pericardial effusion were identified of which 
1399 patients were reported to have underlying malignancy.  Three surgical approaches were 
described in a total of 19 studies with overall success rates ranging from 93.3% to 100% and 
associated complication rates ranging from 4.5% to 10.3%.  The remaining 40 studies reported 4 non-
surgical treatment modalities with success rates of 55.1% to 90.4% and complication rates of 5.9% to 
32%.  
Data from the literature suggest that surgical drainage of the pericardium is superior to non-surgical 
approaches for symptom relief, effusion recurrence, and morbidity; however, the lack of randomised 
controlled trials mean that selection bias remains an important limitation to the field and definitive 
adequately controlled trials should be a priority.  
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1. INTRODUCTION 
 
The pericardium is a frequent site for neoplastic involvement [1].  Although primary tumours of the 
pericardium are rare, metastasis to the heart and pericardium have been reported in up to 21% of 
cancer patients [2].  The majority of these patients remain asymptomatic, but impairment of cardiac 
function contributing to morbidity occurs in one third of cases [3].  Moreover, the potential for life-
threatening cardiac tamponade makes pericardial effusion an important contributor to mortality in 
cancer patients and can require emergency decompression.  
 
Despite aggressive treatment, the prognosis for patients with malignant pericardial effusion remains 
poor and is primarily dictated by the underlying disease [4].  The goal of treatment is therefore 
palliation of symptoms and prevention of effusion recurrence; however, the 'gold standard' treatment 
for malignant pericardial effusion has yet to be defined.  While simple pericardiocentesis is effective 
in the emergency setting of cardiac tamponade, rapid re-accumulation of pericardial fluid commonly 
occurs unless more definitive measures are employed [5]. 
  
Current guidelines recommend a number of approaches, both interventional cardiological and 
surgical; however, no randomised controlled trials have been undertaken to determine the relative 
merits of these treatment modalities [6].  Since this subject was reviewed previously, a number of 
studies have been published but a consensus has yet to emerge regarding the optimal therapeutic 
strategy [7-9].  In this systematic review we set out to address the following question:   
 
In patients with malignant pericardial effusion is surgical treatment superior to interventional 
cardiological management in terms of resolution of symptoms and prevention of effusion recurrence?  
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2. MATERIALS AND METHODS 
 
2.1 Sources of data 
  
We searched Embase from 1974 to May 2013, Medline from 1946 to May 2013, and the Cochrane 
Library database in May 2013 using a formal search strategy.  Combinations of pre-defined Medical 
Subject Heading (MeSH) terms and text words related to the treatment of pericardial effusion in 
cancer patients were used.  The search was conservative to retain any likely contributing studies; 
however, publications in foreign languages were excluded.  In addition, we searched the reference 
lists of publications to identify additional studies of relevance.  
 
2.2 Eligibility criteria 
 
Publications describing the outcomes of patients diagnosed with malignant pericardial effusion by 
imaging or cytology were considered.  Our literature search identified a number of studies reporting 
mixed patient groups with both neoplastic and non-malignant pericardial effusions.  In such cases, 
data extraction was deemed possible only if the outcomes of patients undergoing treatment for 
malignant pericardial effusion were reported separately.  Studies were included only if they reported 
outcomes for a single common treatment modality rather than combinations of treatments (Table 1).  
 
2.3 Data extraction 
 
Results from the online search were imported into a reference management program for detection of 
duplicates.  Next, studies were grouped on a spreadsheet for further analysis.   For each study, 
intervention type, number of patients treated, number of patients surviving the procedure, number of 
effusion recurrences, number of further interventions necessary, and procedure-related complications 
were extracted.  This information was obtained from the body of the text as well as from relevant 
figures.  Data for survival, recurrence and further interventions were presented relative to the total 
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number of cancer patients reported in each study.  Data relating to procedure-related complications 
and side effects were presented relative to the total number of patients treated in each study (Tables 2-
6).  An intervention was considered to be successful if the patient survived the initial procedure and 
did not develop a symptomatic recurrence of their effusion and required no further pericardial 
interventions.  
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3. RESULTS  
 
A search on 31 May 2013 yielded a total of 1181 papers.  Titles and abstracts were reviewed for 
relevance.  The majority were retrospective cohort studies with a small number of prospective studies.  
Duplicates, case reports, review articles, studies superseded by later reports from the same institution, 
and publications containing no quantitative data were excluded.  Only 59 papers fulfilled these criteria 
and were considered further (Fig. 1).  
 
3.1 Single pericardiocentesis  
 
Pericardiocentesis is indicated as an emergency procedure in patients with cardiac tamponade.  Before 
the advent of two-dimensional echocardiography, the procedure was carried out using a blind 
subxiphoid approach, which oftentimes resulted in serious complications [7].  Because two-
dimensional echocardiography permits direct visualisation of cardiac structures and adjacent vital 
organs, the procedure can now be performed with minimal risk.  Two studies reported the use of 
pericardiocentesis as the definitive treatment for malignant pericardial effusion [10, 11] (Table 2).  
Apodaca-Cruza et al. treated a total of 100 patients and reported a success rate of 67% [10].  Effusions 
recurred in the remaining patients, with 29% of patients requiring further intervention.  The rate of 
complications was low at 3% and involved vagal hypotension in all three cases.  Lindenberger et al. 
reported 31 patients treated by pericardiocentesis [11].  Symptomatic relief was achieved in only 
45.2% of patients and was associated with a higher rate of procedure-related complications of 8.3%.  
These included arrhythmias and ventricular puncture.  More than half of the patients (54.8%) required 
further intervention for re-accumulation of pericardial fluid. In neither study were procedure-related 
deaths reported.   
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3.2 Extended catheter drainage  
 
To reduce the rate of effusion recurrence following pericardiocentesis extended catheter drainage has 
been attempted by placement of an indwelling catheter into the pericardial space.  Our search 
identified 6 studies describing the management of malignant pericardial effusion using extended 
catheter drainage [12-17] (Table 3).  Complete resolution of effusion was achieved in only 55.1% of 
cases.  The remainder required further intervention for effusion recurrence.  The rate of complications 
was 12%, arrhythmias being the most common.  No fatalities as a direct consequence of the procedure 
were reported in any of the six studies.  
 
3.3 Pericardial sclerosis  
 
Another well-established approach to reduce the re-accumulation of pericardial fluid is the use of 
sclerosing agents.  These are instilled into the pericardium with the intention to obliterate the potential 
space by causing adhesions between the pericardial layers.  Twenty-two studies described the use of a 
variety of sclerosants to treat malignant pericardial effusion [18-39] (Table 4).  Cisplatin was the most 
widely employed agent being reported in 5 studies with a total of 176 patients [18, 25, 29, 36, 38].  In 
90.3% of these patients, treatment was successful with recurrence of the effusion and procedure-
related morbidity in 9.1% and 13.6%, respectively.  The intrapericardial instillation of tetracycline 
was reported in 2 studies totalling 91 patients with a good overall success rate of 87.9% and only 
8.8% suffering effusion recurrence, but complications and side effects were high at 45.1% [21, 37].  
Thiotepa (N,N'N'-triethylenethiophosphoramide) was used in 3 studies totalling 75 patients [19, 20, 
30].  Of those, 90.7% remained symptom-free and only 6.7% suffered complications.  Forty-five 
patients treated with bleomycin were reported in 3 studies [31, 33, 39].  This agent was able to prevent 
recurrence of effusion in 88.9% of cases, but 26.7% of patients sustained complications, most 
commonly fever, but in one case constrictive pericarditis caused death.  Mitomycin C has been 
reported in only 2 studies totalling 28 participants [23, 27].  Of those, 19 (67.9%) were treated 
successfully but there was one case of pericardial constriction (3.6%).  Three studies, with a total of 
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27 patients, reported the use of mitoxantrone in the treatment of malignant pericardial effusion [28, 
34, 35].  This agent improved clinical status in 24 patients (88.9%) with no reported complications.  
The remaining 4 studies employed a range of unique agents to induce pericardial sclerosis [22, 24, 26, 
32] (Table 5).  These included 2 other tetracycline antibiotics [24, 26] and a second platinum-based 
chemotherapy, carboplatin [32].  Their results were similar to those of tetracycline and cisplatin 
respectively.  The final agent, OK-432 (penicillin-killed Streptococcus pyogenes) was successful in 
the 3 cases treated, but unsurprisingly caused high fever and pain in each of these [22].   
 
3.4 Surgical intervention  
 
Three surgical approaches to the treatment of malignant pericardial effusion have been described in 
19 studies: pericardial fenestration, pericardiectomy, and pericardio-peritoneal shunt insertion [40-58] 
(Table 5).  Pericardial fenestration is the creation of a 'pericardial window' a few centimetres in 
diameter to enable the drainage of pericardial fluid into the pleural space.  Pericardiectomy, the 
surgical resection of part or all of the pericardium, is a more aggressive approach to achieve a more 
complete drainage.  The insertion of a pericardio-peritoneal shunt involves the placement of a Denver 
shunt inflow catheter into the pericardial space with the abdominal end tunnelled subcutaneously 
across the right costal margin through a 3 cm skin incision into the peritoneal cavity.  A pumping 
chamber connected to the shunt is then used for intermittent compression.   
 
The most commonly reported surgical procedure in the literature is pericardial fenestration, which 
was described in 15 studies [40-44, 46, 48-54, 56, 58].  This technique was associated with an overall 
success rate of 93.3%.  Recurrence was reported in 5.7% and complications occurred in 4.5%.  One 
procedure-related death was reported.  Ten out of the 15 studies reported this procedure performed via 
the subxiphoid approach, whereby a short vertical incision is made over the xiphoid process, allowing 
the pericardium to be grasped with surgical clamps and incised directly [40, 41, 46, 48, 50-53, 56, 58].  
This procedure had a success rate of 93.2%, an effusion recurrence rate of 5.5%, and a complication 
rate of 3.9%.  In 3 studies pericardial fenestration was carried out using video-assisted thoracic 
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surgery (VATS) [43, 44, 49, 54].  With the patient under general anaesthesia and using single lung 
ventilation, a thoracoscope is introduced into the thorax.  Two further ports are used to grasp and 
excise a portion of the pericardium to create a pericardial window.  This approach was successful in 
90.9% of cases with 9.1% recurrence overall.  Patients sustained complications in 4.8% of cases.  In 
one study, 26 patients underwent pericardial fenestration by left mini-thoractomy [42].  This achieved 
control of the effusion in 96.2% of cases with only one patient requiring further treatment due to 
recurrence (3.8%) and complications observed in 11.3% of patients.  Another report described the use 
of an alternative approach, known as mediastinoscope-controlled parasternal fenestration (MCPF), to 
create an opening in the pericardium in 22 patients with 100% success and 13.6% complications [54].  
Owing to their low numbers, these single reports must be interpreted with caution.  Pericardiectomy 
was the second most commonly reported surgical procedure [45, 47, 55].  All 3 studies that described 
this approach were performed using VATS with success in all cases and a comparatively higher 
overall rate of complications of 10.3%.  A single study comprising only 4 cases reported the insertion 
of a pericardio-peritoneal shunt to treat malignant pericardial effusion [57]. This approach was 
successful in each patient without reported complications, but as before, the small numbers of this 
series require caution in its interpretation.  
 
3.5 Percutaneous balloon pericardiotomy  
 
Percutaneous balloon pericardiotomy (PBP) requires a guide wire to be is inserted into the pericardial 
space over which a balloon catheter is passed and inflated to create a window in the pericardium.  
Typically, fluid passes from the pericardium into the left pleural space.  We identified 10 studies 
reporting the use of this technique to manage malignant pericardial effusion [59-68] (Table 6).  In a 
majority of these the outcomes were good with control of the effusion in 90.4%. The least good 
outcomes were seen in the smaller studies, suggesting that PBP might best be performed in centres 
with a higher throughput of patients.  There were no procedure-related deaths in any of the 10 studies 
but complications occurred in 32%, the most common being pleural effusion, fever and 
pneumothorax.  
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4. DISCUSSION  
 
Malignant pericardial effusion is an important complication of advanced malignancy that contributes 
significantly to morbidity and also can hasten death.  Although the prognosis of patients with this 
condition is considered to be poor, therapeutic intervention, if successful, can improve quality of life 
and prolong survival.  Despite this, there have been no randomised controlled trials of therapies and 
practices differ widely.  Immediate drainage of the pericardial cavity prevents tamponade and so 
relieves symptoms rapidly.  Simple pericardiocentesis under local anaesthesia can therefore provide 
immediate relief.  It is a relatively quick and straightforward procedure that can be performed by 
physicians and radiologists, and provides fluid for cytological diagnosis. The use of 
echocardiographic-guidance significantly reduces procedure-related complications (5.9%).  Despite 
its usefulness in the acute setting, pericardiocentesis is frequently inadequate in the medium term 
because of its high rate of recurrence.  Even when pericardiocentesis is followed by extended tube 
drainage the results are poor.  Indeed, this approach had only a 55.1% success rate overall when we 
assessed six individual series and was associated with a higher rate of complication (12%).  For this 
reason, in many patients percardiocentesis must be followed by a more definitive procedure.   
 
The intrapericardial instillation of a sclerosant has been widely performed in cases of recurrent 
malignant pericardial effusion.  Overall, when considering all agents together, this approach has a 
success rate of 87.8%, but suffers from a high rate of morbidity (20.5%).  There appears to be little 
difference between the individual agents in terms of their effectiveness, although cisplatin and 
tetracycline have been the most widely reported.  The lack of availability of appropriate preparations 
of tetracycline and its possible higher rate of complications currently make cisplatin a more 
favourable agent.  It may be especially useful for poor surgical candidates.  
 
Surgical decompression of the pericardium appears overall to have a higher success rate of 93.5% and 
to be associated with fewer complications (4.7%). The subxiphoid approach has the advantage that it 
can be performed under local anasthaesia in contrast to VATS, which requires general anaesthesia and 
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single lung ventilation; procedures that can be challenging in critically ill patients.  Although surgical 
treatment options appear to be associated with better clinical outcomes, the lack of adequately 
controlled studies means that selection bias, with the healthier cases more likely to undergo surgery, 
remains a real possibility.  The published studies reported performance status inconsistently.  In only 
6 out of 40 papers that reported a medical-cardiological intervention was information on the 
performance status provided [10, 18, 20, 23, 30, 32], while in only 1 out 19 surgical studies was the 
performance status available [55].  Since these data include only 11 surgical cases, in contrast to 208 
medical cases, statistical comparison would be invalid; however, in both groups the median 
performance status appeared to be equivalent to 3 using the ECOG scale.  Clearly, only with true 
randomisation will this important question be answered.   
 
 
Percutaneous balloon pericardiotomy (PBP) was developed to avoid some of the disadvantages 
associated with surgery, since it can be performed under local anaesthesia and in most cases enables 
early discharge home.  It has a success rate of 90.4% but is associated with more procedure-related 
complications (32%) when compared with conventional surgery.  
 
Sclerosant therapy is appropriate for those unfit for any surgical intervention, but its high risk of 
complications suggests that an intervention that promotes pericardial drainage is the treatment of 
choice for most other cases.  What remains unclear is which procedure is truly superior.  We conclude 
that more and higher quality studies are necessary to address the issues that have been raised by this 
literature review.  A head to head comparison, preferably as a randomised controlled trial comparing 
the two least invasive approaches, pericardial fenestration via the subxiphoid approach versus 
percutaneous balloon pericardiotomy would be immensely valuable to the field.  
 
Limitations  
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A number of limitations in the published literature hamper the comparison of the treatment modalities 
used to treat malignant pericardial effusion.  First, short term success rates are difficult to define 
because survival following a procedure depends significantly on the institution, the clinician, and the 
patient.  Second, metastatic pericardial disease remains a lethal condition.  Prognosis is primarily 
dictated by the non-cardiac progression of the underlying malignancy, thereby making long-term 
success rates difficult to define.  Third, all studies included in this review were observational studies, 
most of them retrospective. This is an important additional factor that limits the interpretation of 
observed differences between results. 
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Table 1. Treatment modalities in the management of malignant pericardial effusion 
Procedure References No. of patients with 
malignancy / total no. 
of patients treated  
 
Single pericardiocentesis  
 
Extended catheter drainage 
 
Pericardial sclerotherapy 
 
Surgery 
 
Percutaneous balloon  
pericardiotomy 
 
 
Total 
 
 
[10, 11] 
 
[12-17] 
 
[18-39] 
 
[40-58] 
 
[59-68] 
 
 
131/220  
 
78/117  
 
474/474 
 
550/1330 
 
166/181 
 
 
 
1399/2322 
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Table 2. Efficacy of single pericardiocentesis  
References Successfully controlled/  
no. of patients with 
malignancy treated (%) 
 
Side effects and complications 
related to the procedure (%) 
 
 
Overall 
 
Apodaca-Cruza et al., 2010 [10]  
 
Lindenberger et al., 2003 [11] 
 
81/131a (61.8) 
 
67/100 (67.0) 
 
14/31 (45.2) 
 
13/220b (5.9) 
 
vagal hypotension (n=3), 
 
arrhythmia (n=6),  
vasovagal reaction (n=2), 
ventricular puncture (n=1), 
breathing difficulties (n=1) 
 
 
a: number of patients with malignancy 
b: total number of patients treated in the study 
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Table 3. Efficacy of extended catheter drainage  
 
References Successfully controlled/  
no. of patients with 
malignancy treated (%) 
 
Side effects and complications 
related to the procedure (%) 
 
 
Overall 
 
 
Buchanan et al., 2003 [12] 
 
 
 
Gatenby et al., 1991 [13] 
 
 
Hingorani et al., 1995 [14] 
 
 
 
Kopecky et al., 1986 [15] 
 
 
 
Medary et al., 1996 [16] 
 
Patel et al., 1987 [17] 
 
 
43/78a (55.1) 
 
 
12/22 (54.5) 
 
 
 
3/12 (25.0) 
 
 
8/9 (88.9) 
 
 
 
5/16 (31.3) 
 
 
 
9/9 (100) 
 
6/10 (60.0) 
 
14/117b (12.0) 
 
 
cardiac injury (n=2), 
pneumothorax (n=1) 
 
 
transient ventricular arrhythmia 
(n=1), hypotension (n=1) 
 
transient atrial fibrillation (n=2), 
pericardial pain (n=1), 
erratic drainage (n=1) 
 
catheter occlusion (n=3),  
infection (n=1), bradycardia and 
symptomatic hypotension (n=1) 
 
none reported 
 
none reported 
 
a: number of patients with malignancy 
b: total number of patients treated in the study 
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Table 4. Efficacy of pericardial sclerotherapy  
 
Agent References Successfully controlled/  
no. of patients with 
malignancy treated (%) 
 
Side effects and 
complications related to 
the procedure (%) 
 
 
Overall 
 
 
Cisplatin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tetracycline 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thiotepa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bischiniotis et al., 2005 
[18] 
 
 
 
 
Lafaras et al., 2009 [25] 
 
 
Maisch et al., 2002 [29] 
 
 
Oida et al., 2010 [36] 
 
Tomkowski et al., 2004 
[38] 
 
 
 
 
 
Davis et al., 1984 [21] 
 
 
 
 
Shepherd et al., 1987 [37] 
 
 
 
 
 
 
 
Bischiniotis et al., 2000 
[19] 
 
Colleoni et al., 1998 [20] 
 
 
 
 
Martinoni et al., 2004 [30] 
 
 
416/474 (87.8) 
 
 
159/176 (90.3) 
 
23/25 (92.0) 
 
 
 
 
 
55/56 (98.2) 
 
 
36/42 (85.7) 
 
 
7/7 (100) 
 
38/46 (82.6) 
 
 
 
80/91 (87.9) 
 
 
30/33 (90.9) 
 
 
 
 
50/58 (82.8) 
 
 
 
 
 
68/75 (90.7) 
 
19/19 (100) 
 
 
19/23 (82.6) 
 
 
 
 
30/33 (90.9) 
 
 
97/474 (20.5) 
 
 
24/176 (13.6) 
 
constriction (n=4), 
transient atrial fibrillation 
(n=3), non-sustained 
ventricular tachycardia 
(n=2) 
 
paroxysmal atrial 
fibrillation (n=5) 
 
myocardial ischaemia 
(n=1) 
 
nausea (n=2) 
 
transient atrial fibrillation 
(n=7) 
 
 
41/91 (45.1) 
 
 
mild transient fever 
(n=12), ventricular 
arrhythmia (n=5),  
atrial fibrillation (n=1) 
 
pain (n=9), transient atrial 
arrhythmia (n=5), fever 
(n=5), catheter occlusion 
(n=4) 
 
 
5/75 (6.7) 
 
atrial fibrillation (n=2), 
vasovagal reaction (n=1) 
 
transient grade III 
thrombocytopenia and 
leukopenia (n=1),  
grade I leukopenia (n=1) 
 
none reported 
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Bleomycin 
 
 
 
 
 
 
 
 
 
 
 
 
Mitomycin C 
 
 
 
 
 
 
 
Mitoxantrone 
 
 
 
 
 
 
 
 
Other 
 
Minocycline 
 
 
 
 
Carboplatin 
 
Aclarubicin 
 
 
OK-432 
 
 
 
 
 
 
 
Maruyama et al., 2007 [31] 
 
 
Moya et al., 2010 [33] 
 
 
 
 
Van Belle et al., 1987 [39] 
 
 
 
 
Kaira et al., 2005 [23] 
 
Lee et al., 1994 [27] 
 
 
 
 
 
Lentzsch et al., 1994 [28] 
 
Musch et al., 2003 [34] 
 
Norum et al., 1998 [35] 
 
 
 
 
Lashevsky et al., 1996 [26] 
 
 
 
 
Moriya et al., 2000 [32] 
 
Kawashima et al., 1999 
[24] 
 
Imamura et al., 1989 [22] 
 
 
 
 
 
 
 
 
40/45 (88.9) 
 
21/22 (95.5) 
 
 
14/18 (77.8) 
 
 
 
 
5/5 (100) 
 
 
19/28 (67.9) 
 
7/8 (87.5) 
 
12/20 (60.0) 
 
 
 
24/27 (88.9) 
 
6/6 (100) 
 
16/16 (100) 
 
2/5 (40.0) 
 
 
 
 
10/14 (71.4) 
 
 
 
 
8/10 (80.0) 
 
5/5 (100) 
 
 
3/3 (100) 
 
 
 
 
 
 
12/45 (26.7) 
 
constrictive pericarditis 
and death (n=1) 
 
mild fever (n=5), atrial 
fibrillation (n=3), 
retrosternal pain (n=1), 
infection (n=1) 
 
transient fever (n=1) 
 
 
1/28 (3.6) 
 
none reported 
 
pericardial constriction 
(n=1) 
 
 
none reported 
 
none reported 
 
none reported 
 
none reported 
 
 
 
 
severe chest pain (n=7),  
pericardial injury (n=2), 
vasovagal reaction (n=1), 
transient fever (n=1) 
 
none reported 
 
none reported 
 
 
high fever, chills and 
chest pain (n=3) 
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Table 5. Efficacy of surgical approaches 
Technique References Successfully controlled/  
no. of patients with 
malignancy treated (%) 
Side effects and 
complications related to 
the procedure (%) 
 
 
Overall 
 
 
Pericardial 
fenestration 
 
 
Subxiphoid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Becit et al., 2005 [40] 
 
Campbell et al., 1992 
[41] 
 
Lajos et al., 1975 [46] 
 
Moores et al., 1995 
[48] 
 
Olson et al., 1995 [50] 
 
 
 
 
 
 
 
 
Osuch et al., 1985 [51] 
 
Sarigul et al., 1999 [52] 
 
 
 
Sugimoto et al., 1990 
[53] 
 
Vassilopoulos et al., 
1995 [56] 
 
Wilkes et al., 1995 [58] 
 
 
 
 
 
 
 
 
514/550a (93.5) 
 
 
474/508a (93.3) 
 
 
 
357/383a (93.2) 
 
 
49/51 (96.1) 
 
22/25 (88.0) 
 
 
15/15 (100) 
 
80/82 (97.6) 
 
 
18/18 (100) 
 
 
 
 
 
 
 
 
6/6 (100) 
 
33/41 (80.5) 
 
 
 
22/24 (91.7) 
 
 
26/26 (100) 
 
 
86/95 (90.5) 
 
 
 
 
 
 
 
 
63/1330b (4.7) 
 
 
56/1258b (4.5) 
 
 
 
42/1079b (3.9) 
 
 
myocardial injury (n=3) 
 
hypotension (n=1) 
 
 
none reported 
 
none reported 
 
 
lobar pneumonia (n=2), 
atrial fibrillation (n=2), 
fascial dehiscence (n=1), 
constrictive pericarditis 
(n=1), intraoperative 
entry into left pleural 
space (n=1) 
 
 
none reported 
 
cardiac arrest (n= 12), 
death (n=7), 
pneumothorax (n=6) 
 
none reported 
 
 
ventricular tachycardia 
(n=1) 
 
prolonged postoperative 
ventilation (n=2), 
infection (n=1), wound 
dehiscence (n=1), death 
(n=1) 
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VATS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left mini-
thoracotomy 
 
 
 
 
 
 
 
 
 
 
MCPF 
 
 
 
 
 
Pericardiectomy 
 
 
VATS 
 
 
 
 
 
 
 
 
 
 
 
 
Pericardio-
peritoneal shunt 
 
Denver shunt 
 
 
 
 
 
 
 
 
Geissbuhler et al., 
1998 [43] 
 
 
 
Georghiou et al., 2005 
[44] 
 
Neragi-Miandoab et al., 
2008 [49] 
 
 
 
 
 
Celik et al., 2012 [42] 
 
 
 
 
 
 
 
 
 
 
Toth et al., 2012 [54] 
 
 
 
 
 
 
 
 
Hazelrigg et al. 1993 
[45] 
 
 
Mack et al. 1993 [47] 
 
 
Uramoto et al. 2010 
[55] 
 
 
 
 
 
Wang et al., 1994 [57] 
 
 
 
 
 
70/77a (90.9) 
 
12/12 (100) 
 
 
 
 
3/3 (100) 
 
 
55/62 (88.7) 
 
 
 
25/26a (96.2) 
 
 
25/26 (96.2) 
 
 
 
 
 
 
 
 
22/22 (100) 
 
22/22 (100) 
 
 
 
38/38a (100) 
 
 
38/38 (100) 
 
18/18 (100) 
 
 
 
9/9 (100) 
 
 
11/11 (100) 
 
 
 
4/4 (100) 
 
 
4/4 (100) 
 
 
 
 
 
5/104b (4.8) 
 
pulmonary embolism 
(n=1), CVA (n=1), 
ventricular arrhythmia 
(n=1) 
 
supraventricular 
arrhythmia (n=1) 
 
ventilation support (n=1) 
 
 
 
6/53b (11.3) 
 
 
infection (n=1), 
ventricular fibrillation 
(n=1), pneumonia and 
sepsis (n=1), pulmonary 
embolism (n=1), heart 
failure (n=1), prolonged 
ventilation (n=1) 
 
 
3/22 (13.6) 
 
dysrhythmia (n=3) 
 
 
 
7/68b (10.3) 
 
 
7/68 (10.3) 
 
atelactasis (n=4), 
pneumonia (n=2), 
arrhythmia (n=1) 
 
none reported 
 
 
none reported 
 
 
 
none reported 
 
 
none reported 
 
a: number of patients with malignancy 
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b: total number of patients treated in the study 
VATS: video-assisted thorascopic surgery 
MCPF: mediastinoscope-controlled parasternal fenestration  
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Table 6. Efficacy of percutaneous balloon pericardiotomy  
 
References Successfully controlled/  
no. of patients with 
malignancy treated (%) 
 
Side effects and complications 
related to the procedure (%) 
 
 
Overall 
 
 
Del Barrio et al., 2002 [59] 
 
 
 
 
 
Di Segni et al., 1995 [60] 
 
 
 
Galli et al., 1995 [61] 
 
 
Jackson et al., 1992 [62] 
 
 
Navarro Del Amo et al., 2002 
[63] 
 
Ovunc et al., 2001 [64] 
 
 
Palacios et al., 1991 [65] 
 
 
Swanson et al., 2008 [66] 
 
 
 
Wang et al., 2002 [67] 
 
 
 
Ziskind et al., 1993 [68] 
 
 
 
150/166a (90.4) 
 
 
8/9 (88.9)  
 
 
 
 
 
7/7 (100) 
 
 
 
10/10 (100) 
 
 
1/2 (50.0) 
 
 
4/4 (100) 
 
 
6/10 (60.0) 
 
 
8/8 (100) 
 
 
25/27 (92.6) 
 
 
 
44/50 (88.0) 
 
 
 
37/39 (94.9) 
 
 
58/181b (32.0) 
 
 
intrapericardial balloon rupture 
(n=1), right ventricular wall 
perforation, hypotension and 
bradycardia (n=1) 
 
 
pain (n=2), profuse bleeding at 
entry site (n=1), bradycardia (n=1) 
 
 
none reported 
 
 
pain (n=1) 
 
 
mild pleural effusion (n=4) 
 
 
pleural effusion (n=2) 
 
 
pleural effusion (n=8) 
 
 
cerebrovascular accident (n=1), 
pneumopericardium (n=1) 
 
 
fever (n=14), mild pneumothorax 
(n=3), balloon breakage (n=1) 
 
 
fever (n=6), profuse bleeding 
(n=1), pleural effusion requiring 
thoracocentesis (n=8), mild 
pneumothorax (n=2) 
 
 
 
a: number of patients with malignancy 
b: total number of patients treated in the study 
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Figure 1. Flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
articles included for data extraction 
(n = 59) 
articles retrieved by database search 
(n = 1181) 
articles assessed for eligibility 
(n = 821) 
duplicates excluded 
(n = 360) 
articles excluded following application of criteria 
(n = 762) 
 
- irrelevant title and abstract (n = 614) 
 
- review articles (n = 19) 
 
- case reports (n = 24) 
 
- no usable data (n = 105) 
